Amylyx Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer developing investigational therapies in endocrine conditions and neurodegenerative diseases. Its 8-K reports furnish quarterly and annual financial results, corporate presentations and material-event disclosures tied to programs such as avexitide for post-bariatric hypoglycemia, AMX0318 and AMX0035.
Proxy and material-event filings describe governance, executive compensation, shareholder voting matters, common-stock registration on the Nasdaq Global Select Market, capital-structure matters, material agreements and program decisions. These records also capture collaboration economics, development-candidate selections, expanded pipeline disclosures and formal updates to clinical programs.
AMLX filed a notice under Rule 144 for a planned sale of restricted shares. The filing covers the proposed sale of 3,448 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 50,515, on or about 02/02/2026 on NASDAQ. The issuer reports 144,693 shares of this class outstanding. The shares to be sold were acquired from the issuer on 02/02/2026 through the vesting of 9,167 restricted stock units, with no separate cash payment required.
Justin B. Klee has filed a Rule 144 notice to sell 15,500 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $227,617, to be sold on or about 02/02/2026 on NASDAQ.
The filing states there are 3,363,898 shares of this class outstanding. The shares to be sold were acquired via vesting of 31,667 restricted stock units from the issuer on 02/02/2026. In the prior three months, Klee sold additional common shares in three transactions totaling several thousand shares.
Amylyx Pharmaceuticals (AMLX) shareholder James M. Frates filed a Rule 144 notice for a planned sale of 3,557 shares of common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of 52,097 and 173,547 shares outstanding.
The shares relate to equity compensation: 10,000 common shares were acquired on 02/02/2026 through the vesting of restricted stock units from the issuer, with no separate cash payment. During the prior three months, Frates sold 3,326 common shares on 01/06/2026 for gross proceeds of 36,954. By signing, he represents that he is not aware of any undisclosed material adverse information about the issuer’s operations.
The Vanguard Group has filed a Schedule 13G reporting beneficial ownership of Amylyx Pharmaceuticals common stock. Vanguard reports beneficial ownership of 5,804,912 shares, representing 5.28% of the class as of the event date of 12/31/2025.
Vanguard has shared voting power over 698,623 shares and shared dispositive power over 5,804,912 shares, with no sole voting or dispositive power. The filing states the securities are held in the ordinary course of business, not to change or influence control, and that Vanguard’s clients have rights to dividends and sale proceeds, with no single client holding more than 5%.
BlackRock, Inc. has filed an amended Schedule 13G reporting a significant ownership stake in Amylyx Pharmaceuticals, Inc. common stock as of 12/31/2025. BlackRock reports beneficial ownership of 7,783,648 shares, representing 7.1 % of Amylyx’s outstanding common stock.
The filing states that BlackRock has sole power to vote or direct the vote over 7,653,538 shares and sole power to dispose or direct the disposition of 7,783,648 shares, with no shared voting or dispositive power. The securities are described as being acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Amylyx.
Amylyx Pharmaceuticals Co-Chief Executive Officer Joshua B. Cohen reported option exercises and related share sales. On January 15, 2026, he exercised 197,182 stock options at $7.57 per share and sold 136,193 shares of common stock at a weighted average price of $13.5895. On January 16, 2026, he exercised an additional 2,818 stock options at $7.57 per share and sold 1,974 shares at a weighted average price of $13.8293. A footnote states that shares were sold to cover option cost and tax obligations under a preset sales plan adopted on November 12, 2025. After these transactions, Cohen directly beneficially owned 3,379,465 shares of Amylyx common stock.
Amylyx Pharmaceuticals Co-Chief Executive Officer and director Justin B. Klee reported option exercises and related share sales. On January 15, 2026, he exercised stock options for 197,153 shares of common stock at an exercise price of $7.57 per share, then sold 136,193 shares at a weighted average price of $13.5827 per share. On January 16, 2026, he exercised options for an additional 2,847 shares at $7.57 and sold 1,995 shares at a weighted average price of $13.8853 per share. According to the footnotes, these sales were made to cover option cost and tax obligations under a preset sales plan adopted on November 12, 2025. After these transactions, Klee directly held 3,379,398 shares of Amylyx common stock.
AMLX filed a Rule 144 notice for a planned insider stock sale. The filing covers the proposed sale of 1,995 shares of the issuer’s common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $26,972.40 as of the filing details.
The shares to be sold were acquired on January 16, 2026 via an exercise of stock options paid in cash on the same date. The notice also lists prior sales of the issuer’s common stock during the past three months for the account of Justin Klee, including 136,193 shares sold on January 15, 2026 for gross proceeds of $1,849,860.26 and 7,715 shares sold on January 6, 2026 for gross proceeds of $85,589.44.
AMLX insider Joshua Barry Cohen has filed a notice of proposed sale of company stock under Rule 144. The filing covers the planned sale of 1,974 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $26,688.48 based on the figures provided. The shares relate to an exercise of stock options on 01/16/2026, paid for in cash and acquired from the issuer on the same date.
The notice states that AMLX had 109,819,569 shares of common stock outstanding. Over the prior three months, sales for Cohen’s account included 136,193 common shares on 01/15/2026 for gross proceeds of $1,850,794.52 and 7,715 common shares on 01/06/2026 for gross proceeds of $85,596.38. By signing, the seller represents that he is not aware of undisclosed material adverse information about the issuer.
An insider of Amylyx filed a Form 144 notice outlining a planned sale of company stock. The filing covers up to 136,193 common shares to be sold through Morgan Stanley Smith Barney LLC on or after January 15, 2026 on the NASDAQ, with an indicated aggregate market value of $1,916,235.51. These shares were acquired the same day through a cash exercise of stock options. The filing also notes that 109,819,569 common shares were outstanding and that the same individual sold 7,715 shares of common stock for $85,596.38 on January 6, 2026. The signer represents that they are not aware of any material adverse, nonpublic information about Amylyx.